IRIX Stock Up 4% As Q1 Loss Narrows Y/Y on Glaucoma Product Growth

IRIDEX posts a narrower year-over-year net loss per share in Q1'26 as strong glaucoma product sales and lower operating costs helped offset weakness in retina sales and supply-chain disruptions.